$TARS insider trading
Over the last 12 months, Tarsus Pharmaceuticals insiders reported no purchases and 29 sales totaling $20.3M across SEC Form 4 filings. 69% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $20.3M 29 events
- Events · 12m
- 29 Form 4 filings, grouped
- Insiders · 12m
- 9 distinct reporters
- 10b5-1 share
- 69% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | LINK WILLIAM J PHDD | ▼ Sale | 12,500 | $78.38 | $980K | -11.7% | plan · 3 tranches |
| Sep 4, 2026 | Lin Elizabeth YeuChief Medical Officer · O | ▼ Sale | 3,180 | $87.5 | $278K | -66.7% | plan · 2 tranches · indirect |
| Sep 4, 2026 | Lin Elizabeth YeuChief Medical Officer · O | ▼ Sale | 10,773 | $87.5 | $943K | -80.9% | plan · 2 tranches |
| Sep 4, 2026 | Neervannan SeshadriChief Operating Officer · O | ▼ Sale | 4,564 | $85 | $388K | -5.5% | plan |
| Sep 4, 2026 | Azamian Bobak R.President/CEO and Board Chair · O·D | ▼ Sale | 10,000 | $90.56 | $906K | -1.2% | plan · 2 tranches · indirect |
| Sep 2, 2026 | Azamian Bobak R.President/CEO and Board Chair · O·D | ▼ Sale | 10,000 | $80.06 | $801K | -1.2% | plan · indirect |
| Sep 2, 2026 | Lin Elizabeth YeuChief Medical Officer · O | ▼ Sale | 1,590 | $80 | $127K | -25% | plan · indirect |
| Sep 2, 2026 | Lin Elizabeth YeuChief Medical Officer · O | ▼ Sale | 9,988 | $77.17 | $771K | -42.9% | plan · 2 tranches |
| Jun 17, 2026 | Azamian Bobak R.President/CEO and Board Chair · O·D | ▼ Sale | 10,000 | $61.55 | $615K | -1.2% | plan · 2 tranches · indirect |
| Jun 16, 2026 | Farrow Jeffrey SSee Remarks · O | ▼ Sale | 14,396 | $60.95 | $877K | -20.2% | — |
| Jun 15, 2026 | Goodrich KatherineD | ▼ Sale | 2,954 | $62.08 | $183K | -57% | plan |
| Jun 15, 2026 | LINK WILLIAM J PHDD | ▼ Sale | 12,500 | $62.12 | $776K | -10.5% | plan · 2 tranches |
| Mar 20, 2026 | Neervannan SeshadriChief Operating Officer · O | ▼ Sale | 2,989 | $66.75 | $200K | -3.5% | plan |
| Mar 19, 2026 | Lin Elizabeth YeuChief Medical Officer · O | ▼ Sale | 1,144 | $68.36 | $78K | -4.7% | 3 tranches |
| Mar 19, 2026 | Wahl BryanGeneral Counsel · O | ▼ Sale | 12,440 | $68.36 | $850K | -16.3% | 3 tranches |
| Mar 19, 2026 | Whitfield Dianne C.Chief Human Resources Officer · O | ▼ Sale | 12,274 | $68.36 | $839K | -25.9% | 3 tranches |
| Mar 19, 2026 | Azamian Bobak R.President/CEO and Board Chair · O·D | ▼ Sale | 34,603 | $68.34 | $2.4M | -50.9% | 3 tranches |
| Mar 19, 2026 | Neervannan SeshadriChief Operating Officer · O | ▼ Sale | 11,324 | $68.21 | $772K | -11.7% | 3 tranches |
| Mar 19, 2026 | Mottiwala AzizChief Commercial Officer · O | ▼ Sale | 13,056 | $68.36 | $893K | -17.5% | 3 tranches |
| Mar 19, 2026 | Farrow Jeffrey SSee Remarks · O | ▼ Sale | 6,430 | $68.36 | $440K | -12.9% | 3 tranches |
| Mar 16, 2026 | LINK WILLIAM J PHDD | ▼ Sale | 12,500 | $68.79 | $860K | -9.7% | plan · 3 tranches |
| Mar 4, 2026 | Neervannan SeshadriChief Operating Officer · O | ▼ Sale | 8,366 | $76.67 | $641K | -10.6% | plan |
| Jan 2, 2026 | Whitfield Dianne C.Chief Human Resources Officer · O | ▼ Sale | 15,565 | $80.67 | $1.3M | -40% | plan · 4 tranches |
| Dec 24, 2025 | Azamian Bobak R.President/CEO and Board Chair · O·D | ▼ Sale | 6,000 | $82.51 | $495K | -0.7% | plan · late · 2 tranches · indirect |
| Dec 16, 2025 | Whitfield Dianne C.Chief Human Resources Officer · O | ▼ Sale | 7,397 | $80.1 | $592K | -16% | plan |
| Dec 16, 2025 | Lin Elizabeth YeuChief Medical Officer · O | ▼ Sale | 2,078 | $79.5 | $165K | -8.7% | — |
| Dec 15, 2025 | LINK WILLIAM J PHDD | ▼ Sale | 10,446 | $81.07 | $847K | -100% | plan · 2 tranches · indirect |
| Dec 15, 2025 | LINK WILLIAM J PHDD | ▼ Sale | 12,500 | $81.43 | $1.0M | -8.8% | plan · 3 tranches |
| Sep 24, 2025 | Azamian Bobak R.President/CEO and Board Chair · O·D | ▼ Sale | 6,000 | $55.37 | $332K | -0.7% | plan · indirect |
| Sep 8, 2025 | LINK WILLIAM J PHDD | ▼ Sale | 27,116 | $57 | $1.5M | -15.9% | — |
| Aug 11, 2025 | Azamian Bobak R.President/CEO and Board Chair · O·D | ▼ Sale | 6,000 | $50 | $300K | -0.7% | plan · indirect |
Every $TARS filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Tarsus Pharmaceuticals filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $TARS feed.